Type I interferons as vaccine adjuvants against infectious diseases and cancer

Bracci, Laura; Sorsa, Valentina La; Belardelli, Filippo; Proietti, Enrico

doi:10.1586/14760584.7.3.373

Cited by 49 publications

(41 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IFN-I produced by miDC and pDC in response to viruses potentially affects hematopoiesis since it is established that high levels of IFN-I can ablate hematopoietic precursors leading to acquired anemia (33) or skewing of precursor development (41). IFN-I act as adjuvants and activate and enhance DC, CTL, and B cell responses (42) and thus potentially enhance innate and adaptive immune responses to BM-encountered Ag. In the case of miDC, the production of IFN-I as well as their ability to stimulate T cells suggests their direct involvement in T cell activation.…”

Section: Discussionmentioning

confidence: 99%

Nonplasmacytoid, High IFN-α–Producing, Bone Marrow Dendritic Cells

O’Keeffe

Fancke

Suter

et al. 2012

The Journal of Immunology

View full text Add to dashboard Cite

Plasmacytoid dendritic cells (pDC) are the producers of type I IFNs in response to TLR9 ligands. However, we have found that when bone marrow is depleted of pDC, the IFN-α produced in response to TLR9 ligands is not fully removed. We assign the source of this non-pDC IFN-α as a newly described DC type. It displays the high IFN-α producing activity of pDC but to a more limited range of viruses. Unlike pDC, the novel DC display high T cell stimulation capacity. Moreover, unlike mouse pDC, they are matured with GM-CSF and are less prone to apoptosis upon activation stimuli, including viruses. We propose that these DC constitute a novel bone marrow inflammatory DC type, ideally geared to linking innate and adaptive immune responses in bone marrow via their potent IFN-α production and high T cell stimulatory capacity.

show abstract

Section: Discussionmentioning

confidence: 99%

Nonplasmacytoid, High IFN-α–Producing, Bone Marrow Dendritic Cells

O’Keeffe

Fancke

Suter

et al. 2012

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…Local delivery can be achieved with pharmaceutical formulations and gene therapy approaches (70). In our opinion, the clinical use of recombinant IFN-a as a vaccine adjuvant should be reconsidered and new investigations carried out with an eye to clinical applications (71).…”

Section: Future Perspectivesmentioning

confidence: 99%

Direct Effects of Type I Interferons on Cells of the Immune System

Hervás-Stubbs

Perez-Gracia²,

Rouzaut³

et al. 2011

Clinical Cancer Research

419

355

View full text Add to dashboard Cite

Type I interferons (IFN-I) are well-known inducers of tumor cell apoptosis and antiangiogenesis via signaling through a common receptor interferon alpha receptor (IFNAR). IFNAR induces the Janus activated kinase-signal transducer and activation of transcription (JAK-STAT) pathway in most cells, along with other biochemical pathways that may differentially operate, depending on the responding cell subset, and jointly control a large collection of genes. IFNs-I were found to systemically activate natural killer (NK) cell activity. Recently, mouse experiments have shown that IFNs-I directly activate other cells of the immune system, such as antigen-presenting dendritic cells (DC) and CD4 and CD8 T cells. Signaling through the IFNAR in T cells is critical for the acquisition of effector functions. Cross-talk between IFNAR and the pathways turned on by other surface lymphocyte receptors has been described. Importantly, IFNs-I also increase antigen presentation of the tumor cells to be recognized by T lymphocytes. These IFN-driven immunostimulatory pathways offer opportunities to devise combinatorial immunotherapy strategies. Clin Cancer Res; 17(9); 2619-27. Ó2011 AACR.

show abstract

“…This approach, which was initially reported to augment antitumour responses, implicates that therapeutic activation of DCs may indeed represent a powerful strategy for the treatment of chronic HBV and HCV infection. IFNα, the currently used immune modulatory treatment for both chronic HBV and HCV infection, is known to enhance DC differentiation, maturation, migration and survival (reviewed in Bracci et al 101). The effect of HBV, HCV and their viral proteins on DC function may, however, interfere with this treatment.…”

Section: Dcs As Targets and Tools For Antiviral Treatmentmentioning

confidence: 99%